Table 2.
Clinicopathological characteristics associated with the phenotypic signatures of the new IRs (LAG-3, TIM-3, and TIGIT) in a validation group of 96 primary ccRCC tumour samples (COHORT 4).
| Characteristic | All patients (n = 96) | p value COHORT 4 vs COHORT 1 | IR profile | p value | ||||
|---|---|---|---|---|---|---|---|---|
| LAG-3 n = 26 (27%) | TIM-3 n = 38 (40%) | TIGIT n = 32 (33%) | LAG-3 vs TIM-3 | LAG-3 vs TIGIT | TIM-3 vs TIGIT | |||
| Age, yr, median, (IQR) | 60 (52-68) | 0.412 | 63 (55-73) | 57 (52-70) | 65 (51-70) | 0.682 | 0.420 | 0.653 |
| Gender, no (%): | 0.192 | 0.132 | 0.061 | 0.745 | ||||
| Male | 77 (80%) | – | 17 (65%) | 32 (84%) | 28 (88%) | – | – | – |
| Female | 19 (20%) | – | 9 (35%) | 6 (16%) | 4 (13%) | – | – | – |
| Nuclear grade, no (%): | 0.006 | 0.010 | 0.061 | 0.695 | ||||
| G1 + G2 | 80 (83%) | – | 17 (65%) | 35 (92%) | 28 (88%) | – | – | – |
| G3 + G4 | 16 (17%) | – | 9 (35%) | 3 (8%) | 4 (13%) | – | – | – |
| Pathological T stage, no (%): | <0.001 | 0.293 | 0.274 | 1.000 | ||||
| pT1 + pT2 | 83 (86%) | – | 20 (77%) | 34 (89%) | 29 (91%) | – | – | – |
| pT3 + pT4 | 13 (14%) | – | 6 (23%) | 4 (11%) | 3 (9%) | – | – | – |
| Venous invasion, no (%): | 0.523 | 0.132 | 0.563 | 0.381 | ||||
| Yes | 23 (24%) | – | 9 (35%) | 6 (16%) | 8 (25%) | |||
| No | 73 (76%) | – | 17 (65%) | 32 (84%) | 24 (75%) | |||
| Tumour size, mm, median (IQR) | 40 (30–52) | <0.001 | 49 (28–60) | 35 (30–50) | 37 (29–50) | 0.461 | 0.269 | 0.666 |
p values were determined with a two-tailed Mann–Whitney U-test or Fisher’s exact test.